Xilio Therapeutics Strikes Lucrative Deal with Gilead Sciences
Company Announcements

Xilio Therapeutics Strikes Lucrative Deal with Gilead Sciences

Xilio Therapeutics (XLO) has issued an announcement.

Xilio Development, Inc. secured an exclusive license agreement with Gilead Sciences for the clinical-stage cancer treatment XTX301, with the potential for Gilead to take over development and commercialization. Xilio will receive an upfront payment of $43.5 million and could earn up to $604 million more, plus tiered royalties on sales. The agreement also includes an equity investment by Gilead and an initial stock purchase, with provisions for additional private placements. This strategic financial collaboration aims to advance Xilio’s clinical trials and overall development, while also providing the company with significant funding and the possibility of future payments based on milestones and sales.

Find detailed analytics on XLO stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXilio Therapeutics Reports Q3 2024 Progress and Financials
TipRanks Auto-Generated NewsdeskXilio Therapeutics Advances Cancer Drug and Financial Outlook
TheFlyXilio Therapeutics announces initial data from Phase 1C trial for XTX101
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App